Pharmacology
Pharmacist Interventions to Reduce Modifiable Bleeding Risk Factors Using HAS-BLED in Patients Taking Warfarin
Use of risk scores and pharmacist follow-up could reduce bleeding risk in patients on anticoagulation therapy.
John Thomas and Anne Hyson are Physicians, John Sellinger is a Psychologist, Marcia Mecca is a Geriatrician and the Medical Director of the IMPROVE Clinic, and Rebecca Brienza is a Physician and Director of the West Haven CoEPCE at VA Connecticut Health Care System. Annette Gardner is an Assistant Professor at the University of California, San Francisco. Kristina Niehoff is a Pharmacist at Vanderbilt University in Nashville, Tennessee. Sean Jeffery is a Clinical Professor of Pharmacy Practice at the University of Connecticut School of Pharmacy in Storrs. Marcia Mecca and Rebecca Brienza are Assistant Professors at Yale University School of Medicine in New Haven, Connecticut.
Author disclosures
The authors report no actual or potential conflicts of interest with regard to this article.
Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies.
IMPROVE also combines key components of interprofessional education—an enriched clinical training model and knowledge of medications in an elderly population—into a training activity that complements other CoEPCE activities. The model not only has strengthened CoEPCE partnerships with other VA departments and specialties, but also revealed opportunities for collaboration with academic affiliates as a means to break down traditional silos among medicine, nursing, pharmacy, geriatrics, and psychology.
IMPROVE combines key components of interprofessional education, including all 4 CoEPCE core domains, to provide hands-on experience with knowledge learned in other aspects of the CoEPCE training program (eg, shared decision-making strategies for eliciting patient goals, weighing risks and benefits in complex clinical situations). Physician and NP trainees work together with trainees in pharmacy and health psychology in the complex approach to polypharmacy. IMPROVE provides the framework for an interprofessional clinic that could be used in the treatment of other complex or high-risk chronic conditions.
An opportunity for improvement and expansion includes increased patient involvement (as patients continue to learn they have a team working on their behalf). Opportunities exist to connect with patients who have several clinicians prescribing medications outside the CoEPCE to provide comprehensive care and decrease medication complexity.
The CoEPCE has been proactive in increasing the visibility of IMPROVE through multiple presentations at local and national meetings, facilitating collaborations and greater adoption in primary care. Individual and collective IMPROVE components can be adapted to other contexts. For example, the 20-minute geriatrics education session and the forms completed prior and during the patient visit can be readily applied to other complex patients that trainees meet in clinic. Under stage 2 of the CoEPCE program, the CoEPCE is developing an implementation kit that describes the training process and includes the medication worksheet, assessment tools, and directions for conducting the group visit.
It is hoped that working collaboratively with the West Haven COEPCE polypharmacy faculty, a similar model of education and training will be implemented at other health professional training sites at Yale University in New Haven, Connecticut. Additionally, the West Haven CoEPCE is planning to partner with the other original CoEPCE program sites to implement similar interprofessional polypharmacy clinics.
Use of risk scores and pharmacist follow-up could reduce bleeding risk in patients on anticoagulation therapy.
This quality improvement project used an educational brochure to help older veterans reduce their benzodiazepine use.
There was no difference identified in the rate of falls immediately prior to and following initiation of ergocalciferol 50,000 IU self-...